Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

's results are bolstered by a well executed commercial strategy, availability of compelling clinical data, and a robust presence within scientific peer-review forums. In addition, recent regulatory actions both in the U.S. and in Europe continue to validate the efficacy, safety and tolerability of IMBRUVICA, and strengthen its brand within the CLL prescriber, patient and payor environments."

GAAP and Non-GAAP expensesNon-GAAP R&D expenses for the quarter ended June 30, 2014 were $37.5 million, compared to $24.2 million for the quarter ended June 30, 2013. Non-GAAP SG&A expenses were $36.2 million for the quarter ended June 30, 2014, compared to $11.6 million for the quarter ended June 30, 2013. Reconciliation between certain GAAP and Non-GAAP measures is provided at the end of this press release.

GAAP R&D expenses for the quarter ended June 30, 2014 were $45.7 million, compared to $27.9 million for the quarter ended June 30, 2013. GAAP SG&A expenses for the quarter ended June 30, 2014 were $45.0 million, compared to $14.7 million for the quarter ended June 30, 2013.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general, Janssen is responsible for approximately 60% of development costs and the Company is responsible for approximately 40% of development costs. Generally, costs associated with commercialization will be included in determining pre-tax profit or pre-tax loss relating to IMBRUVICA, and are to be shared 50% by the Company and 50% by Janssen. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of IMBRUVICA related R&D expenses, SG&A expenses, and offset by pre-tax commercial profits for each calendar year. The Company recognizes amounts incurred in excess of the annual cap (Excess Amounts) as a reduction to costs and expenses since the Company's repayment of Excess Amounts to Janssen is contingent and would b
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... INC. (NYSE: RMD ) today announced that it ... on Thursday, January 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Jan. 28 Some 18-20 million Americans are at ... to 10 percent have been diagnosed.  Studies prove that fatality is ... OSA can be readily and successfully treated. , Historically, OSA ... a technician directly monitoring a patient,s breathing.  Many who suspect they ...
... DIEGO , Jan. 28 Conatus Pharmaceuticals Inc. ... evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin ... of the triple combination will be assessed after up to ... medical need in HCV patients who have not responded to ...
Cached Medicine Technology:NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 2NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 3Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... Park, Colo. The top executive search firm in the ... than 900 healthcare executives into organizations. , Estes ... access hospital and level IV trauma center, with a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Hands On Mobile ... available. The Spa On Wheels has been transformed into ... from the outside world seems to disappear. The Virtual Tour ... massages, facials, spa parties, corporate events and more. , The ... Spa On Wheels which is actually an overhauled Winnebago. Marla ...
(Date:12/19/2014)... Slone Partners , a national recruitment firm ... and laboratory testing industries, has promoted Leslie Loveless ... announcement comes after a year of expansion by ... Boston and several new additions to the team. ... experience," said Adam Slone, Chief Executive Officer. “Diagnostics ...
(Date:12/19/2014)... 19, 2014 The Hermitage Club ... in Southern Vermont’s Deerfield Valley, announced today that it ... classic rock songs. , Three time Grammy Award ... private concert followed by a trail naming ceremony. Hermitage ... names include: “I’m Alright” the theme song for the ...
(Date:12/19/2014)... Amy Norton HealthDay ... Children born to moms who were exposed to high levels ... risk of developing autism, a U.S. study suggests. Researchers ... between 1990 and 2002, those exposed to the most air ... baby who later developed autism. And exposure during the third ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... , , THURSDAY, Nov. 1 (HealthDay News) -- Heart disease ... for an individual,s brothers or sisters, too, U.S. researchers ... among brothers, the Johns Hopkins University team found. For ... chest pain from blocked arteries, the other is 20 ...
... SACRAMENTO, Calif., Nov. 1 Always Best Care ... California,areas. America,s premier In-Home Care, Assisted Living Placement ... seniors in Granada,Hills/Sherman Oaks can now rely on ... over a decade, a caring relationship has been ...
... Addition to Postal Service Social Awareness Stamp,Series, WASHINGTON, ... next year to help raise awareness about Alzheimer,s disease,as ... John,Potter announced today, on the first day of both ... "With the Alzheimer,s Awareness commemorative stamp, we,ll ask,Americans ...
... the current issue of Clinical Pharmacology & Therapeutics, ... Bioethics and Johns Hopkins Berman Institute of Bioethics ... vaccine debate, and its effects on ethical and ... was a major achievement for cervical cancer prevention ...
... program,s launch, study found , , THURSDAY, Nov. 1 (HealthDay ... Part D prescription drug benefit increased the number of ... $32 billion to Medicare, a new study concludes. , ... Health Affairs , the study authors noted that many ...
... a statement,from ADA President Mark J. Feldman:, "The ... Camp (R-MI) for introducing legislation that will help bring ... tribal areas,where too many people lack sufficient access to ... "The Native American Full Access to Dental Care ...
Cached Medicine News:Health News:Siblings Often Share Heart Risks 2Health News:Siblings Often Share Heart Risks 3Health News:Announcing Always Best Care Senior Services Expansion Into the Granada Hills/Sherman Oaks, California Areas 2Health News:Alzheimer's Disease to be Highlighted on Stamp Next Year 2Health News:A missed shot: The failure of HPV vaccination state requirements 2Health News:A missed shot: The failure of HPV vaccination state requirements 3Health News:Medicare Drug Plan Cost $32 Billion in 2006 2Health News:Medicare Drug Plan Cost $32 Billion in 2006 3Health News:Statement by ADA President Mark J. Feldman on the Native American Full Access to Dental Care Act 2
... Advanced diagnostic capabilities combined with ease ... best product in its class. Ideal for ... a complete system for Uroflowmetry, cystometry, leak ... (8) configurations are available which make the ...
... combined with ease of use make the ... class. Ideal for office or hospital-based urodynamics, ... Uroflowmetry, cystometry, leak point pressure, or urethral ... which make the OM-5 flexible enough to ...
Windows-Based Urodynamics for Fast and Straightforward. Testing For Clinics Where Logic and Efficiency are at a Premium...
... simple: to provide better care for your patients. ... lower urinary tract symptoms (LUTS) includes urodynamics for ... to increases in reimbursement, it now makes financial ... are sending them to someone who does not ...
Medicine Products: